New hope for Hard-to-Treat stomach cancer: drug cocktail trial launches
NCT ID NCT06630130
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This phase II trial is testing a combination of three drugs—trastuzumab deruxtecan, capecitabine, and rilvegostomig—in people with HER2-positive, locally advanced stomach cancer that cannot be removed by surgery right away. The goal is to see if giving these drugs before and after surgery can shrink the tumor and improve outcomes. The study will enroll 50 adults and track safety, tumor response, and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab deruxtecan (Enhertu), capecitabine (Xeloda), and rilvegostomig (AZD2936)
- What this could lead to
- If successful, this could point toward a new combination treatment that shrinks or controls advanced gastric cancer before and after surgery, potentially improving survival.
- What could go wrong
- This is a small, early-phase (phase II) trial with only 50 participants, so results may not apply to all patients. The drugs can cause serious side effects, and the combination may not work better than existing therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE LOCALLY ADVANCED UNRESECTABLE GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a modified stomach bypass speed up recovery in advanced gastric cancer?
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
- Electric acupoint therapy may speed digestion and ease pain after stomach cancer surgery
- Could a simple painkiller combo replace opioids after stomach cancer surgery?
- Default option nudge may boost cancer screening in High-Risk groups
- One-Click autofocus could speed up stomach scopes